Heart failure complicating myocardial infarction. A report of the peruvian registry of ST-elevation myocardial infarction (PERSTEMI)
- Manuel Chacón-Diaz(corresponding author),
- Ofelia Araoz-Tarco,
- Walter Alarco-León,
- Oscar Aguirre-Zurita,
- Maritza Rosales-Vidal,
- Patricia Rebaza-Miyasato
- ,
- Instituto Nacional Cardiovascular Carlos Alberto Peschiera Carrillo, EsSalud
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 447-453 (7 pages)Journal (Volume, Issue Number)
Archivos de cardiologia de Mexico (Volume 88, Issue 5)Publication milestones
- Published - 12/2018
Publication status
ISSN
1405-9940Publication IDs
- Scopus: 85059223114
- PubMed: 29728297
Abstract
Objectives: The aim of this study is to determine the incidence, associated factors, and 30-day mortality of patients with heart failure (HF) after ST elevation myocardial infarction (STEMI) in Peru. Methods: Observational, cohort, multicentre study was conducted at the national level on patients enrolled in the Peruvian registry of STEMI, excluding patients with a history of HF. A comparison was made with the epidemiological characteristics, treatment, and 30 day-outcome of patients with (Group 1) and without (Group 2) heart failure after infarction. Results: Of the 388 patients studied, 48.7% had symptoms of HF, or a left ventricular ejection fraction <40% after infarction (Group 1). Age > 75 years, anterior wall infarction, and the absence of electrocardiographic signs of reperfusion were the factors related to a higher incidence of HF. The hospital mortality in Group 1 was 20.6%, and the independent factors related to higher mortality were age > 75 years, and the absence of electrocardiographic signs of reperfusion. Conclusions: Heart failure complicates almost 50% of patients with STEMI, and is associated with higher hospital and 30-day mortality. Age greater than 75 years and the absence of negative T waves in the post-reperfusion ECG are independent factors for a higher incidence of HF and 30-day mortality.
